Resveratrol plus low-dose hydroxyurea compared to high-dose hydroxyurea alone is more effective in γ-globin gene expression and ROS reduction in K562 cells
- 1 July 2022
- journal article
- research article
- Published by Taylor & Francis in Natural Product Research
- Vol. 37 (6) , 985-989
Abstract
Hydroxyurea (HU) is an anti-cancer drug that is used for the treatment of hemoglobinopathies as a γ-globin inducer. However, its dose-dependent effects have hampered its clinical reliability. Resveratrol (RSV) is an antioxidant and γ-globin inducer. The present study aimed to assess their combined effects on the γ-globin gene expression and reactive oxygen species (ROS) level of K562 cells. The results indicated that the γ-globin gene expression was approximately two folds higher in the group treated with RSV 50 µM + HU 25 µM in comparison to HU 100 μM alone (***p < 0.001). However, there was an inverse relationship between the expression of γ-globin gene and HU concentration in the combined groups. Furthermore, the combinations of RSV and HU significantly reduced ROS levels compared to single drugs. Overall, the combination of these compounds was an appropriate strategy for increasing γ-globin expression, reducing oxidant levels, and alleviating the adverse effects of HU. Graphical AbstractKeywords
This publication has 12 references indexed in Scilit:
- Effects of Resveratrol on the Mechanisms of Antioxidants and Estrogen in Alzheimer’s DiseaseBioMed Research International, 2019
- Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cellsBlood, 2018
- Hydroxyurea for nontransfusion-dependent β-thalassemiaHematology/Oncology and Stem Cell Therapy, 2017
- Erratum to: Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years’ follow-up in EgyptAnnals of Hematology, 2016
- Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta‐thalassemiaEuropean Journal of Haematology, 2013
- Synthesis and Antiproliferative Activity of Quinolone Nucleosides Against the Human Myelogenous Leukemia K‐562 Cell LineArchiv der Pharmazie, 2013
- Hydroxyurea in Sickle Cell Disease: Drug ReviewIndian Journal of Hematology and Blood Transfusion, 2013
- The plasticity and potential of leukemia cell lines to differentiate into dendritic cellsOncology Letters, 2012
- New isocratic high-performance liquid chromatographic procedure to assay the anti-sickling compound hydroxyurea in plasma with ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1998
- Successful Use of Hydroxyurea in β-Thalassemia MajorNew England Journal of Medicine, 1997